Articles

TAK1 is a pivotal therapeutic target for tumor progression and bone destruction in myeloma

Dept. of Histology-Oral Histology and Dept. of Hematology, Tokushima University,Tokushima, Japan;
Dept. of Hematology and Orthodontics and Dentofacial Orthopedics,Tokushima University, Japan;
Dept. of Hematology and Orthodontics and Dentofacial Orthopedics,Tokushima University, Japan;
Department of Hematology, Tokushima University, Tokushima, Japan;
Dept of Hematology, Tokushima University & University of Medical Sciences, Ulaanbaatar, Mongolia;
Department of Hematology, Tokushima University, Tokushima, Japan;
Department of Hematology, Tokushima University, Tokushima, Japan;
Dept. of Hematology and Orthodontics and Dentofacial Orthopedics,Tokushima University, Japan;
Dept. of Hematology and Orthodontics and Dentofacial Orthopedics,Tokushima University, Japan;
Department of Hematology, Tokushima University, Tokushima, Japan;
Department of Hematology, Tokushima University, Tokushima, Japan;
Department of Hematology, Tokushima University, Tokushima, Japan;
Department of Hematology, Tokushima University, Tokushima, Japan;
Department of Hematology, Tokushima University, Tokushima, Japan;
Division of Transfusion Medicine and Cell Therapy, Tokushima University Hospital, Tokushima, Japan;
Department of Chronomedicine, Tokushima University, Tokushima, Japan;
Department of Histology and Oral Histology, Tokushima University, Tokushima, Japan;
Fujii Memorial Institute of Medical Sciences, Tokushima University, Tokushima, Japan
Department of Hematology, Tokushima University, Tokushima, Japan;
Haematologica Early view Apr 9, 2020 https://doi.org/10.3324/haematol.2019.234476